Searchable abstracts of presentations at key conferences in endocrinology

ea0077s4.2 | Understanding pathogenesis: development of novel treatments | SFEBES2021

Thyroid eye disease

Kahaly George J

Graves’ orbitopathy or thyroid eye disease (TED) represents the most common extra thyroidal manifestation of Graves’ disease. Smoking and radioactive iodine therapy are the most important modifiable risk factors. Thyrotropin receptor and insulin-like growth factor-1 receptor crosstalk, orbital inflammatory infiltration and activation of orbital fibroblasts lead to perpetuation of orbital inflammation a...

ea0092ps3-24-03 | Thyroid Eye Disease | ETA2023

Teprotumumab efficacy in european and us study sites participating in the phase 2, optic (Phase 3) and optic-x pivotal trials

Kahaly George , Fu Qianhong , Holt Robert

Background: Teprotumumab showed significant improvements vs placebo for the treatment of thyroid eye disease (TED) in clinical trials1,2 and is approved in the United States (US) but currently not in the EU. Differences exist in baseline patient demographics and characteristics between EU and US patients. Here we examine outcomes in these 2 cohorts.Methods: Data from the EU and US sites for patients in the teprotumumab group (n =121) from the in...

ea0084op-05-26 | Oral Session 5: Autoimmunity | ETA2022

Prospective single blind, usa-based, multicenter comparison of tsh-receptor antibody immunoassays

Lupo Mark , Little Amy , Hatun Burak , Kahaly George

Objective: The performance of two functional bioassays and two immunoassays for the measurement of TSHR-Ab was assessed in this multicenter study.Methods: Two-hundred two subjects (median age 54 years, 162 female, 80%), with well-documented thyroid disorders and controls were prospectively enrolled in a consecutive, unselected manner. Antibody measurements were performed in a blinded manner using the Bridge (Siemens, performed at the Dartmouth-Hitchcock ...

ea0084ps3-12-110 | Graves’ Disease 2 and Orbitopathy | ETA2022

Linear mixed model analysis of quality of life scores in patients with thyroid eye disease treated with teprotumumab from three 24-week clinical trials

Kahaly George , Qashqai Anahita , Barretto Naina , Vesel Claudia , Holt Robert

Objectives: Teprotumumab, an IGF1-receptor antagonist, has been shown in three clinical trials to markedly improve the clinical course of Thyroid Eye Disease (TED) or Graves’ Orbitopathy (GO) with significant improvements noted in inflammation, proptosis, and diplopia. Furthermore, compared to placebo moderate-to-large improvements were noted in the total, appearance (AP), and visual function (VF) as measured by EUGOGO GO quality of life (GO-QOL) scores after 24 weeks of ...

ea0092op-09-04 | Oral Session 9: Thyroid Eye Disease | ETA2023

Novel, rapid, sensitive bioassay for thyrotropin receptor stimulatory antibodies- a multicenter, single blind study

Kahaly George , Bossowski Artur , Frommer Lara , Hatun Burak , Wolf Jan , Lupo Mark

Background: Autoantibody mimicry of hormone action at the thyrotropin receptor (TSH-R) and aberrant signaling of TSH-R by autoantibodies (TSH-R-Ab) causes autoimmune thyroid disease (AITD), hyperthyroidism and hypothyroidism, both of which affect millions of patients worldwide. In this multicenter, single blind study, the specificity, sensitivity and performance of a novel bioassay for stimulatory TSH-R-Ab were tested.Methods: TSH-R-Ab were measured in a...

ea0092ps1-05-01 | Thyroid hormone diagnostics 1 | ETA2023

Functional thyrotropin receptor autoantibodies in women with thyroid autoimmunity and the impact of ovarian stimulation

Poppe Kris , Frommer Lara , Hatun Burak , Autin Candice , Wolff Fleur , Kahaly George

Background: Thyroid autoimmunity (TAI) is the most important cause of hypothyroidism in the general population, and its prevalence is higher in women of subfertile couples.1 Women pregnant after an assisted reproductive technology (ART) with TAI carry a higher risk of a first trimester miscarriage rate compared to women without TAI. Several reasons could be underlying such as thyroid dysfunction, older age, an immune imbalance, and the presence of thyrotropin recept...

ea0092ps1-05-05 | Thyroid hormone diagnostics 1 | ETA2023

Multicenter, 5-assay comparison of thyrotropin receptor blocking antibodies

George Augustine , Bossowski Artur , Frommer Lara , Hatun Burak , Konig Jochem , Lupo Mark , Wolf Jan , Kahaly George

Background: Thyrotropin receptor (TSH-R) blocking autoantibodies (TBAb) are present in 10-15% of patients with autoimmune thyroid disease (AITD). TBAb are functional and clinically relevant. This multicenter study compares the sensitivity and specificity of five immunoassays for the measurement of TBAb and introduces a novel and ultra-rapid TBAb bioassay.Methods: Serum samples from AITD patients were tested with two TSH-R binding immunoassays (Cobas e411...

ea0022p866 | Thyroid | ECE2010

Selenium and pentoxifylline in patients with mild Graves’ orbitopathy: Results of a randomized placebo-controlled double-blind clinical trial

Marcocci Claudio , Altea Maria Antonietta , Kahaly George , Pitz Susanne , Krassas Gerasimos , Boboridia Kostas , Bartalena Luigi , Sivelli Mario , von Arx Georg , Stahl Matthias , Nardi Marco , Mourits Maarten , Baldeschi Leilo , Pinchera Also , Wiersinga Wilmar , EUGOGO Group

We studied 152 patients with Graves’ disease mild orbitopathy (GO), with a disease duration of <18 months, who had been euthyroid for at least 2 months after antithyroid drug or surgery, or 6 months after 131-Iodine. No patient received previous treatment for GO, except for local measures. Patients were randomized to receive either selenium (SE), an antioxidant (as selenium selenite, 100 (g b.i.d), or pentoxifylline (PF), an anti-inflammatory and antifibrotic agent (6...